Metropolis Healthcare Limited — Investor Meet, 10-08-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Metropolis Healthcare reported strong Q1 FY27, with revenue up 17% YoY to ₹450 Cr, driven by 10% patient volume growth. EBITDA margins expanded 210 bps to 25.2% (₹113 Cr), and PAT rose 26% to ₹57 Cr.

Management eyes 14-15% revenue growth for FY27 and 27-28% EBITDA margins long-term. Growth is fueled by 13.5% B2C volume, 6% B2B volume, 17% Specialty, and 22% TruHealth growth. The company is adding ~500 centers, focusing on deeper penetration in Tier 2/3 markets. Core Diagnostics integration is nearing completion, strengthening North India presence. Outlook: Confident on sustainable, profitable growth.